| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Rhelion Life Sciences Corp: Rhelion's Filament issued new U.S. patent for PEX010 | 3 | Stockwatch | ||
| RHELION LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| Do | Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New United States Patent, Extending the Broadest Natural Psilocybin Patent Estate | 442 | Newsfile | A new United States patent, "Psychoactive Alkaloid Extraction and Composition with Inhibited Dephosphorylation," has been issued by the United States Patent and Trademark Office, adding to the intellectual... ► Artikel lesen | |
| Di | Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to UCSF for Phase 1 Trial of Psilocybin in Healthy Older Adults with Low Well-Being | 486 | Newsfile | Filament has shipped PEX010 to the University of California, San Francisco (UCSF) for OAD1, a Phase 1 trial of psilocybin in healthy older adults with low well-being.Toronto, Ontario--(Newsfile Corp.... ► Artikel lesen | |
| 10.11. | Rhelion Life Sciences Corp: Rhelion's Filament ships PEX010 for Sleepy study | 2 | Stockwatch | ||
| 09.11. | Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to King's College London | 453 | Newsfile | Filament has shipped PEX010 to King's College London for SLEEPY, a feasibility study of giving psilocybin just before sleep.Toronto, Ontario--(Newsfile Corp. - November 9, 2026) - Rhelion Life Sciences... ► Artikel lesen | |
| 03.11. | Rhelion Life Sciences Corp: Rhelion's Filament Health ships PEX010 to USC | 6 | Stockwatch | ||
| 03.11. | Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Southern California for the Expanded Mindfulness Assisted Psychedelic Therapy Trial | 562 | Newsfile | Filament has shipped PEX010 to the Keck School of Medicine of USC for the first order under the expanded supply agreement for its Mindfulness Assisted Psychedelic Therapy trial.Toronto, Ontario--(Newsfile... ► Artikel lesen | |
| 02.11. | Rhelion Life Sciences Corp: Rhelion Life Sciences completes IBEX011 extraction | 6 | Stockwatch | ||
| 02.11. | Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes New Extraction of IBEX011, Its Naturally Derived Ibogaine Drug Candidate, and Commences Stability Testing | 393 | Newsfile | Filament has completed a new extraction of IBEX011The Company expects Filament to begin stability testing on the new extract shortlyToronto, Ontario--(Newsfile Corp. - November 2, 2026) - Rhelion Life... ► Artikel lesen | |
| 28.10. | Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Agreement to Supply PEX010 to Linkoping University for PsiloSAD Trial in Social Anxiety Disorder | 364 | Newsfile | Filament has signed a supply and licensing agreement with Linköping University in Sweden for PEX010 in the PsiloSAD clinical trial in social anxiety disorder.Toronto, Ontario--(Newsfile Corp. - October... ► Artikel lesen | |
| 16.10. | Rhelion Life Sciences Corp: Rhelion's Filament enters supply deal with Epsylon | 6 | Stockwatch | ||
| 16.10. | Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Supply Belgium's First Psilocybin Compassionate Use Program, to Help Open the Door to Patient Access for Treatment-Resistant Depression | 660 | Newsfile | Filament has signed an agreement to supply PEX010 to Epsylon ASBL for what the Company believes will be the first program in Belgium to give patients access to psilocybin outside a clinical trial.Filament... ► Artikel lesen | |
| 14.10. | Rhelion Life Sciences Corp: Rhelion reappoints Carhart-Harris as scientific adviser | 9 | Stockwatch | ||
| 14.10. | Rhelion Life Sciences Corp.: Rhelion Life Sciences Reappoints Dr. Robin Carhart-Harris as Scientific Advisor | 709 | Newsfile | Dr. Robin Carhart-Harris has signed a new agreement to serve as Scientific Advisor to Rhelion Life Sciences and its wholly owned subsidiary Filament Health.Toronto, Ontario--(Newsfile Corp. - October... ► Artikel lesen | |
| 09.10. | Rhelion Life Sciences Corp: Rhelion Life to supply psilocybin to UCSF meth trial | 2 | Stockwatch | ||
| 08.10. | Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Licence Agreement with the University of California, San Francisco for a Phase 2 Trial of Psilocybin in Methamphetamine Use Disorder Among People with HIV | 619 | Newsfile | Filament will supply PEX010 to a University of California, San Francisco trial testing whether a single dose of psilocybin can be used to help people living with HIV reduce methamphetamine use, a condition... ► Artikel lesen | |
| 29.09. | Rhelion Life Sciences Corp: Rhelion unit ships PEX010 for Calgary PTSD trial | 9 | Stockwatch | ||
| 29.09. | Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Calgary for Phase 2 Trial of Psilocybin-Assisted Therapy for PTSD in Survivors of Intimate Partner Violence | 405 | Newsfile | Filament has shipped PEX010 to the University of Calgary for PsiPTSD, a Phase 2 trial of psilocybin-assisted therapy for post-traumatic stress disorder in survivors of intimate partner violence.Toronto... ► Artikel lesen | |
| 25.09. | Rhelion Life Sciences Corp: Rhelion unit expands PEX010 supply for Italian trial | 6 | Stockwatch | ||
| 25.09. | Rhelion Life Sciences Corp.: Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resistant Depression in Italy | 624 | Newsfile | Following authorization of the TEMPO trial under the European Union Clinical Trials Regulation, Filament has expanded its supply agreement with the University G. d'Annunzio of Chieti-Pescara to support... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 53,36 | -2,41 % | Bayer feiert FDA-Durchbruch mit 26 Prozent weniger Schlaganfällen - Mesoblast bereitet nächste Zelltherapie auf Milliardenmarkt vor | ||
| NOVO NORDISK | 34,485 | +0,13 % | Aktien Europa: Überwiegend freundlicher Wochenauftakt | PARIS/LONDON/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte sind mehrheitlich mit moderaten Gewinnen in die neue Börsenwoche gestartet. Der EuroStoxx 50 notierte gegen Mittag 0,2 Prozent tiefer... ► Artikel lesen | |
| NOVARTIS | 137,18 | +0,10 % | 27 % weniger neue Medikamente: Trump setzt Europa unter Druck: Jetzt droht ein Medikamenten-Engpass | © Foto: Patrick Seeger/dpaTrumps Arzneimittelpolitik trifft Europa: Die Markteinführung neuer Medikamente sinkt um 27 Prozent. Pharmakonzerne schützen ihre Gewinne, Patienten leiden Enthaltene Werte:... ► Artikel lesen | |
| AURORA CANNABIS | 3,768 | -0,69 % | Das zwingt Anleger zum Handeln: Cannabisaktien am Wendepunkt: Warum Canopy, Tilray & Co. jetzt im Fokus stehen | © Foto: adobe.stock.comDie Quartalsberichte der Cannabis-Unternehmen boten Licht und Schatten - oder sollte man besser Hoffnung und Resignation sagen? Die Unterschiede hätten nicht größer sein können.... ► Artikel lesen | |
| SANOFI | 84,44 | -0,05 % | Dank Organspende zurück ins Leben: Sanofi unterstützt aktuelle Debatte zur Novelle des Transplantationsgesetzes | Frankfurt/Main (ots) - Für viele schwer kranke Menschen ist eine Transplantation die einzige lebensrettende Therapieoption. Ein Spenderorgan kann ihnen den Weg in ein neues, aktives Leben eröffnen.... ► Artikel lesen | |
| GSK | 22,010 | +0,87 % | JEFFERIES stuft GSK auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Jefferies hat GSK anlässlich der vom Analysehaus ausgerichteten "Global Healthcare Conference" in London mit einem Kursziel von 2100 Pence auf "Hold" belassen. David Redfern... ► Artikel lesen | |
| ELI LILLY | 1.228,80 | -0,07 % | Milliardeninvestitionen in Psychedelika: Eli Lilly und AbbVie verlagern Fokus auf Behandlungslogistik | ||
| CANOPY GROWTH | 0,400 | +1,16 % | Why Is Canopy Growth Stock Falling Friday? | ||
| STADA ARZNEIMITTEL | - | - | Enzymatica AB: STADA launches Virustad in Germany - based on Enzymatica's ColdZyme technology | STADA has launched the oral spray Virustad in the German pharmacy market. Virustad is built on Enzymatica's clinically documented ColdZyme® technology. The launch follows the partnership agreement signed... ► Artikel lesen | |
| TILRAY BRANDS | 1,710 | -0,58 % | Tilray-Aktie: Turnaround-Chance bei diesem Cannabis-Titel | Tilray Brands hat sich in den vergangenen Jahren grundlegend verändert. Der einst auf Cannabis spezialisierte Konzern setzt inzwischen verstärkt auf alkoholische Getränke und weitere Konsumgüter, um... ► Artikel lesen | |
| TEVA PHARMACEUTICAL INDUSTRIES | 39,240 | 0,00 % | Teva und Neurocrine scheiterten: Schafft NeuroThera jetzt den Tourette-Durchbruch? | ||
| VERTEX PHARMACEUTICALS | 468,75 | -0,26 % | 50 Prozent der neuen US-Arzneien waren Orphan Drugs: Warum BioMarin, Vertex und NurExone kleine Märkte anders entwickeln | ||
| ABBOTT LABORATORIES | 93,98 | -0,11 % | Dividendenbekanntmachungen (16.11.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,63 USD EUR ABBVIE INC US00287Y1091 1,73 USD EUR AGCO CORPORATION US0010841023 0,3 USD 0... ► Artikel lesen | |
| INNOCAN PHARMA | 0,880 | +3,04 % | InnoCan Pharma: Quartalszahlen und Finanzierung - die Aktie bleibt ein Wackelkandidat | ||
| TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -2- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameCA83013Q8719 CORE... ► Artikel lesen |